Neuregulin1 gene variants as a biomarker for cognitive impairments in patients with schizophrenia

• E.S.Ananloo ^[2] ; S.Yoosefee ^[3] ; M.Karimipour ^[1]
  1. [1] Pasteur Institute of Iran

     Pasteur Institute of Iran

     Irán

     
  2. [2] Department of Psychosomatic, Imam Khomeini Hospital Complex (IKHC), School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran/ Department of Neuroscience, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran
  3. [3] Neuroscience Research Center, Qom University of Medical Sciences, Qom, Iran / Spiritual Health Research Center, Qom University of Medical Sciences, Qom, Iran

  Mostrar afiliaciones +
• Localización: European journal of psychiatry, ISSN 0213-6163, Vol. 34, Nº 1, 2020, págs. 11-19
• Idioma: inglés
• DOI: 10.1016/j.ejpsy.2019.12.004
• Enlaces
  • Texto completo
• Resumen

  • Abstract Background and objectives This study aimed to determine whether the selected neuregulin1 (NRG1) gene variants (rs2439272 and rs6988339) are associated with schizophrenia, and Cognitive Impairments Associated with Schizophrenia (CIAS).

    Methods Participants with schizophrenia (N = 276) and healthy controls (N = 193) were enrolled. Cognitive assessment using the Wisconsin card sorting test (WCST) and Wechsler adult intelligence scale and genotyping for selected variants of NRG1 were performed.

    Results For both the rs2439272 and rs6988339, compared to healthy controls, we found significant higher frequencies of the G allele and the GG genotype in all and male participants with schizophrenia, and with all Wechsler adult intelligence score (WAIS) and Wisconsin card sorting test (WCST) scores (except for non-perseverative score) in all, male and female participants.

    Conclusions There was an association between rs2439272, rs6988339 of NRG1 variants and schizophrenia and CIAS (intelligence and executive functions).